These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Variant histology of pediatric nodular lymphocyte-predominant Hodgkin lymphoma with IgD and CD30 expression. Ali N; Moussa E; Khorshed E; Zaghloul MS; Elnashar A; Abdalla A Pediatr Blood Cancer; 2023 Nov; 70(11):e30647. PubMed ID: 37638819 [TBL] [Abstract][Full Text] [Related]
10. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Binkley MS; Rauf MS; Milgrom SA; Pinnix CC; Tsang R; Dickinson M; Ng AK; Roberts KB; Gao S; Balogh A; Ricardi U; Levis M; Casulo C; Stolten M; Specht L; Plastaras JP; Wright C; Kelsey CR; Brady JL; Mikhaeel NG; Hoppe BS; Terezakis SA; Picardi M; Della Pepa R; Kirova Y; Akhtar S; Maghfoor I; Koenig JL; Jackson C; Song E; Sehgal S; Advani RH; Natkunam Y; Constine LS; Eich HT; Wirth A; Hoppe RT Blood; 2020 Jun; 135(26):2365-2374. PubMed ID: 32211877 [TBL] [Abstract][Full Text] [Related]
11. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260 [TBL] [Abstract][Full Text] [Related]
12. Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. Gotti M; Sciarra R; Pulsoni A; Merli F; Luminari S; Zerbi C; Trentin L; Re A; Rusconi C; Viviani S; Rossi A; Cocito F; Botto B; Meli E; Pinto A; Dogliotti I; Gini G; Puccini B; Ricci F; Nassi L; Fabbri A; Liberati AM; Merli M; Filippi AR; Bonfichi M; Zoboli V; Tartaglia G; Annechini G; D'Elia GM; Del Giudice I; Alvarez I; Visentin A; Pravato S; Dalceggio D; Pagani C; Ferrari S; Cristinelli C; Lazic T; Ferretti VV; Ricardi U; Arcaini L Hemasphere; 2023 Apr; 7(4):e837. PubMed ID: 37034003 [TBL] [Abstract][Full Text] [Related]
13. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era. King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755 [TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl. Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142 [TBL] [Abstract][Full Text] [Related]
15. [Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma]. Dourthe ME; Simonin M; Rigaud C; Haouy S; Montravers F; Ducou Le Pointe H; Garnier N; Minard-Colin V; Jo Molina T; Boudjemaa S; Leblanc T; Landman-Parker J Bull Cancer; 2023 Sep; 110(9):968-977. PubMed ID: 37062647 [TBL] [Abstract][Full Text] [Related]
16. Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East. Akhtar S; Rauf MS; Khafaga Y; Al-Kofide A; Elhassan TAM; Elshenawy MA; Nadri J; Mushtaq AH; Bakshi N; Shamayel M; Al-Sweedan S; Sarwar S; Maghfoor I BMC Cancer; 2021 Apr; 21(1):351. PubMed ID: 33794818 [TBL] [Abstract][Full Text] [Related]
17. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414 [TBL] [Abstract][Full Text] [Related]
18. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677 [TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141 [TBL] [Abstract][Full Text] [Related]
20. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]